Brief: Epigenomics Retains Greg Hamilton As CEO Through 2025
24/01/2022 06:06
Jan 24 (Reuters) - EPIGENOMICS AG ECXn.DE :
* SUPERVISORY BOARD OF EPIGENOMICS AG RETAINS GREG HAMILTON
AS
CHIEF EXECUTIVE OFFICER THROUGH DEVELOPMENT OF EPI PROCOLON
'NEXT-GEN' COLORECTAL CANCER SCREENING TEST
* GREG HAMILTON RETAINED AS CEO THROUGH 2025
Source text for Eikon: ID:nEQ92TF7qa
Further company coverage: ECXn.DE
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Epigenomics AG
See all newsU.S. FDA advisers back approval for Guardant's blood-based cancer test (updated)
U.S. FDA advisers back approval for Guardant's cancer test
Brief: Epigenomics Says Closing Of Agreement On The Acquisition Of Almost All Assets And Adjustment Of Guidance For 2023
Brief: Epigenomics AG Says It Entered Into Agreement On The Acquisition Of Almost All Assets With New Day Diagnostics LLC
Brief: Epigenomics Says Chief Scientific Officer Andrew Lukowiak Resigns